Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sleep Apnea01:21

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heart rate and vascular responses to spontaneous arousals following experimental sleep restriction.

American journal of physiology. Heart and circulatory physiology·2026
Same author

Three's Company: Cardiac myxoma, bicuspid aortic valve with severe aortic stenosis and ascending thoracic aortic aneurysm uncovered by anaplasmosis infection.

IDCases·2026
Same author

Capnocytophaga canimorsus in Iliac Artery Mycotic Aneurysm: The Role of Molecular Diagnostics.

The American journal of case reports·2025
Same author

Neuro-ophthalmic outcomes after carotid intervention for ocular symptoms.

Journal of vascular surgery·2024
Same author

Balloon protection of the mesenteric-renal vessels during embolectomy of acute paravisceral aortic occlusion.

Journal of vascular surgery cases and innovative techniques·2024
Same author

JCS 2023 Guideline on Diagnosis and Treatment of Sleep Disordered Breathing in Cardiovascular Disease.

Circulation journal : official journal of the Japanese Circulation Society·2024

Related Experiment Video

Updated: Jun 18, 2026

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
04:53

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Published on: October 18, 2024

Obstructive sleep apnea and heart failure.

Andrew D Calvin1, Felipe N Albuquerque, Taro Adachi

  • 1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA.

Current Treatment Options in Cardiovascular Medicine
|November 26, 2009
PubMed
Summary

Obstructive sleep apnea (OSA) is a serious concern for heart failure (HF) patients, particularly those with obesity or hypertension. Diagnosis and treatment of OSA, often with continuous positive airway pressure, are recommended, though its impact on HF outcomes is still under investigation.

More Related Videos

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

Related Experiment Videos

Last Updated: Jun 18, 2026

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
04:53

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Published on: October 18, 2024

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

Area of Science:

  • Cardiology
  • Sleep Medicine
  • Pulmonology

Background:

  • Obstructive sleep apnea (OSA) presents significant risks for patients with heart failure (HF).
  • Certain conditions like obesity, metabolic syndrome, systemic hypertension, and pulmonary hypertension increase OSA suspicion in HF patients.
  • The interplay between OSA and HF requires careful consideration for optimal patient management.

Purpose of the Study:

  • To highlight the importance of considering OSA in heart failure patients.
  • To outline diagnostic and therapeutic strategies for OSA in the context of HF.
  • To emphasize the need for further research on the impact of OSA treatment on HF outcomes.

Main Methods:

  • Clinical evaluation for suspected OSA in HF patients.
  • Polysomnography for accurate OSA diagnosis and differentiation from central sleep apnea.
  • Implementation of continuous positive airway pressure (CPAP) and alternative therapies for OSA.
  • Standard HF management including medications and fluid balance optimization.

Main Results:

  • OSA diagnosis requires specialized sleep evaluation, including polysomnography.
  • Continuous positive airway pressure (CPAP) is a primary treatment for OSA in HF patients.
  • Alternative treatments like mandibular advancement devices or surgery are available for CPAP-intolerant patients.
  • Optimization of fluid balance may reduce OSA severity in HF patients.

Conclusions:

  • OSA should be actively screened for and managed in heart failure patients, especially those with comorbidities.
  • While treatments exist for OSA, their definitive impact on reducing hospitalizations or mortality in HF patients remains uncertain.
  • Integrated management of both HF and OSA is crucial, with ongoing research needed to clarify treatment efficacy.